Atopic dermatitis (AD) or atopic eczema is a very common skin condition due to skin inflammation. It is usually a long-term condition where the skin becomes itchy, dry, cracked, sore and red. About one in every five children in the UK have AD. This condition may have impacts on the affected child’s quality of life. AD cannot be cured although it can improve significantly, or even clear completely, in some children as they get older. There is an unmet need for safe and effective long-term treatment for moderate-to-severe AD particularly in children.
Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.
Baricitinib acts by selectively and reversibly blocking the janus-associated kinase (JAK) enzymes that mediate the pathways involved in the inflammatory process in AD and other inflammatory diseases. Baricitinib is taken orally and is currently licensed for the treatment of moderate to severe active rheumatoid arthritis in adult patients that have not responded well to other therapies. If licensed, baricitinib will offer an additional treatment option for adults with moderate to severe AD.